Pluvicto Moves Earlier in PSMA-Positive Prostate Cancer
FDA approval expands Pluvicto into PSMA-positive metastatic hormone-sensitive prostate cancer, enabling earlier radioligand therapy alongside ARPI treatment before castration resistance.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.